Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Southwest Airlines Co — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Southwest Airlines Co trades at $39.3 (market cap $19.89B). The key difference: Southwest Airlines Co is far larger — about 7× Dyne Therapeutics Inc. Common Stock's market cap, and Southwest Airlines Co pays a 1.77% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Southwest Airlines Co for 66 Days on average.
| DYN | LUV | |
|---|---|---|
Market Cap | $2.86B | $19.89B |
Volume | 3,341,579 | 3,985,163 |
Sector | Health | Industrials |
52-Week High | $26.78 | $54.80 |
52-Week Low | $14.60 | $29.67 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $2.18B | $22.98B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Southwest Airlines (LUV) trades at $39.34, down 3.48% today, showing bearish technical signals with mixed earnings performance. The company reported a Q2 2026 EPS beat ($0.94 vs $0.51 expected) but missed Q1 expectations. Fundamentals show modest revenue growth to $28.06B in 2025 with a thin 2.78% net margin, though valuation appears reasonable with P/S of 0.71 and P/E of 25.41. Recent news highlights Southwest's commercial transformation initiatives targeting over $2B EBIT in 2026.
LUV presents a turnaround opportunity with analyst consensus target of $49.61 offering 26% upside, though near-term headwinds from high fuel costs and competitive pressures persist. The stock's bearish technical setup and volatile earnings history require careful risk management, but successful execution of revenue initiatives could drive significant shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
